WARNING: RISK FOR HEPATOTOXICITY
PROMACTA may cause hepatotoxicity:
ā—¸Measure serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), and bilirubin prior to initiation of PROMACTA, every 2 weeks during the dose adjustment phase and monthly following establishment of a stable dose. If bilirubin is elevated, perform fractionation.
ā—¸Evaluate abnormal serum liver tests with repeat testing within 3 to 5 days. If the abnormalities are confirmed, monitor serum liver tests weekly until the abnormality(ies) resolve, stabilize, or return to baseline levels.
ā—¸Discontinue PROMACTA if ALT levels increase to ≥3X the upper limit of normal (ULN) and are:
ā—¸persistent for ≥4 weeks, or
ā—¸accompanied by increased direct bilirubin, or
ā—¸accompanied by clinical symptoms of liver injury or evidence for hepatic decompensation.
Because of the risk for hepatotoxicity and other risks [see Warnings and Precautions (5.1-5.6)], PROMACTA is available only through a restricted distribution program called PROMACTA CARES. Under PROMACTA CARES, only prescribers, pharmacies, and patients registered with the program are able to prescribe, dispense, and receive PROMACTA. To enroll in PROMACTA CARES, call 1-877-9-PROMACTA [see Warnings and Precautions].
PROMACTA (eltrombopag) Tablets contain eltrombopag olamine, a small molecule thrombopoietin (TPO) receptor agonist for oral administration. Eltrombopag interacts with the transmembrane domain of the TPO receptor (also known as cMpl) leading to increased platelet production. Each tablet contains eltrombopag olamine in the amount equivalent to 25 mg or 50 mg of eltrombopag free acid.
PROMACTA is indicated for the treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. PROMACTA should be used only in patients with ITP whose degree of thrombocytopenia and clinical condition increases the risk for bleeding. PROMACTA should not be used in an attempt to normalize platelet counts.
Published Studies Related to Promacta (Eltrombopag)
Efficacy of eltrombopag in management of bleeding symptoms associated with
chronic immune thrombocytopenia. 
Bleeding is of particular clinical importance in the management of chronic immune
thrombocytopenia (ITP), which involves impaired platelet production and
accelerated destruction. We report the first comprehensive analysis of the impact
of eltrombopag on bleeding in five clinical studies of adult chronic ITP: two
6-week phase 2 (TRA100773A) and phase 3 (TRA100773B) studies; a 6-month phase 3
study (RAISE); a phase 2 repeat-dose study (REPEAT); and a phase 3 extension
Population pharmacokinetics of eltrombopag in healthy subjects and patients with chronic idiopathic thrombocytopenic purpura. [2011.06]
The population pharmacokinetics of eltrombopag were characterized in healthy subjects (n = 111) and patients with idiopathic thrombocytopenic purpura (ITP) (n = 88) using nonlinear mixed-effects modeling. The final model was evaluated via graphical diagnostics and through predictive check and nonparametric bootstrap procedures...
Clinical pharmacokinetics, platelet response, and safety of eltrombopag at supratherapeutic doses of up to 200 mg once daily in healthy volunteers. [2011.03]
This was a double-blind, placebo-controlled, randomized, parallel, dose-escalation study to assess the pharmacokinetics, platelet response, safety, and tolerability of supratherapeutic doses of eltrombopag (100 mg, 150 mg, and 200 mg once daily) administered for 5 days to 33 healthy adult volunteers...
Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. [2011.01.29]
BACKGROUND: Eltrombopag is an oral thrombopoietin receptor agonist for the treatment of thrombocytopenia. We aimed to compare the response to once daily eltrombopag versus placebo in patients with chronic immune thrombocytopenia during a 6-month period... INTERPRETATION: Eltrombopag is effective for management of chronic immune thrombocytopenia, and could be particularly beneficial for patients who have not responded to splenectomy or previous treatment. These benefits should be balanced with the potential risks associated with eltrombopag treatment. FUNDING: GlaxoSmithKline. Copyright (c) 2011 Elsevier Ltd. All rights reserved.
Clinical pharmacokinetics, platelet response, and safety of eltrombopag at
supratherapeutic doses of up to 200 mg once daily in healthy volunteers. 
This was a double-blind, placebo-controlled, randomized, parallel,
dose-escalation study to assess the pharmacokinetics, platelet response, safety,
and tolerability of supratherapeutic doses of eltrombopag (100 mg, 150 mg, and
200 mg once daily) administered for 5 days to 33 healthy adult volunteers...
Clinical Trials Related to Promacta (Eltrombopag)
EXTEND (Eltrombopag Extended Dosing Study) [Recruiting]
An open-label, dose-adjustment, extension study to evaluate the safety and efficacy of
eltrombopag for the treatment of subjects with idiopathic thrombocytopenic purpura (ITP) who
have previously been enrolled in an eltrombopag trial. This study will allow adjustment of
the eltrombopag dose to achieve an individualized dose and schedule for each subject. In
addition, the ability to reduce the dose of concomitant ITP medications in the presence of
eltrombopag, while maintaining platelet counts = 50,000/microL will be investigated.
Efficacy of Eltrombopag to Improve Thrombocytopenia of MYH9-related Disease [Recruiting]
The term MYH9-related disease (MYH9RD) includes four genetic disorders: May-Hegglin anomaly,
Sebastian syndrome, Fechtner syndrome, and Epstein syndrome. All these disorders derive from
mutation of a unique gene, named MYH9, and they have been recognized as different clinical
presentations of a single illness that was named MYH9RD. All patients affected by MYH9RD
present since birth with thrombocytopenia, which can result in a variable degree of bleeding
diathesis; some of them subsequently develop additional clinical manifestations, such as
renal damage, sensorineural hearing loss, and/or presenile cataracts. Eltrombopag is an oral
thrombopoietin receptor agonist that stimulates proliferation and differentiation of
megakaryocytes, the bone marrow cells that produce blood platelets. This drug is effective
in increasing platelet count in healthy volunteers, as well as in patients affected by some
acquired thrombocytopenias, such as idiopathic thrombocytopenic purpura and HCV related
thrombocytopenia. The purpose of this study is to determine if eltrombopag, administered
orally at the dose of 50 or 75 mg/daily for up to 6 weeks, is effective in increasing
platelet count of patients affected by MYH9RD. Further aims of this study are to test if
eltrombopag is effective in reducing bleeding tendency of MYH9RD patients; to evaluate
safety and tolerability of eltrombopag in patients with MYH9RD; to evaluate in vitro
function of platelets produced during therapy in patients responding to this drug.
Platelet Function in Idiopathic Thrombocytopenic Purpura (ITP) Patients With Eltrombopag [Recruiting]
This is a single-center, prospective, controlled study with one eltrombopag treatment group
and 2 control groups, one on standard steroid treatment, and another one untreated.
The aim of the study is to determine the effect of Thrombopoietin Receptor (MPL) agonists on
shear-induced platelet activation.
A Pilot Study of Oral Vorinostat Plus Oral Eltrombopag Support in Patients With Lymphoma (VEIL) [Recruiting]
Vorinostat is a drug (Histone Deacetylase Inhibitor [HDACi]) administered orally that has
been approved in United States for the patients with cutaneous Tcell lymphoma (CTCL) who
have progressive, persistent or recurrent disease on or following two systemic therapies.
In the early period of treatment with vorinostat, some patients may experience low platelet
counts. Therefore this study will be examining the combination of these two medications
(Vorinostat and eltrombopag) to assess if eltrombopag can overcome the low platelets during
treatment with vorinostat.
Eltrombopag is a drug administered orally designed to mimic the protein thrombopoietin,
which causes the body to make more platelets. Eltrombopag has been registered in Australia
and approved overseas to treat patients with chronic ITP (Immune Thrombocytopenia Purpura) a
disease where patients destroy their own platelets very rapidly and thus develop low
platelet count) but it is not registered and it is not yet known whether eltrombopag can
increase platelet counts in patients treated with the HDACi.
The aim of this project is to test whether Vorinostat and eltrombopag can be safely
combined, and to test whether they are effective in participants with T-cell lymphoma
involving the skin or patients with relapsed/refractory follicular lymphoma (FL), marginal
zone lymphoma (MZL), or mantle cell lymphoma (MCL)
A total of 25 people with Cutaneous T cell lymphoma/ CTCL, marginal zone lymphoma,
follicular lymphoma or mantle cell lymphoma will be recruited in this study.
Eltrombopag and the Bcl-xL Pathway in Idiopathic Thrombocytopenic Purpura (ITP) [Recruiting]
The purpose of this study is to further evaluate the effects that eltrombopag has on
platelets in subjects with chronic ITP. Eltrombopag is approved by the Food and Drug
Administration (FDA) for the treatment of low platelets in patients with chronic ITP. It is
being further studied by GlaxoSmithKline in other conditions associated with low platelets.
This research study is being done because eltrombopag has been shown to increase platelet
counts in a different way than other therapies for ITP. The investigators want to further
study how eltrombopag affects subjects and their platelets to determine how the study drug
should best be used in ITP treatment.
Reports of Suspected Promacta (Eltrombopag) Side Effects
Drug Ineffective (59),
Platelet Count Decreased (41),
Myelodysplastic Syndrome (28),
Platelet Count Increased (28),
Liver Disorder (23),
Pulmonary Embolism (19), more >>
Page last updated: 2014-12-01